Lombardi, Y., Raynaud, M., Schatzl, M., Mayer, K. A., Diebold, M., Patel, U. D., … Böhmig, G. A. (2025). Estimating the efficacy of felzartamab to treat antibody-mediated rejection using the iBox prognostication system. Am J Transplant, 25(5), 1130–1132. https://doi.org/10.1016/j.ajt.2024.12.004

Lombardi, Yannis, Marc Raynaud, Martina Schatzl, Katharina A. Mayer, Matthias Diebold, Uptal D. Patel, Eva Schrezenmeier, et al. “Estimating the efficacy of felzartamab to treat antibody-mediated rejection using the iBox prognostication system.” Am J Transplant 25, no. 5 (May 2025): 1130–32. https://doi.org/10.1016/j.ajt.2024.12.004.

Lombardi Y, Raynaud M, Schatzl M, Mayer KA, Diebold M, Patel UD, et al. Estimating the efficacy of felzartamab to treat antibody-mediated rejection using the iBox prognostication system. Am J Transplant. 2025 May;25(5):1130–2.

Lombardi, Yannis, et al. “Estimating the efficacy of felzartamab to treat antibody-mediated rejection using the iBox prognostication system.” Am J Transplant, vol. 25, no. 5, May 2025, pp. 1130–32. Pubmed, doi:10.1016/j.ajt.2024.12.004.

Lombardi Y, Raynaud M, Schatzl M, Mayer KA, Diebold M, Patel UD, Schrezenmeier E, Akifova A, Budde K, Loupy A, Böhmig GA. Estimating the efficacy of felzartamab to treat antibody-mediated rejection using the iBox prognostication system. Am J Transplant. 2025 May;25(5):1130–1132.